Cargando…

Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors

OBJECTIVE(S): The aim of this study was to determine metastasis rate in patients with well-differentiated grade1 (G1) and grade 2 (G2) gastroenteropancreatic neuroendocrine tumors (GEP NETs) using the gallium-68 DOTATATE positron emission tomography/computed tomography ((68)Ga-DOTATATE PET/CT). This...

Descripción completa

Detalles Bibliográficos
Autores principales: Komek, Halil, Ansal Balci, Tansel, Can, Canan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mashhad University of Medical Sciences 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661313/
https://www.ncbi.nlm.nih.gov/pubmed/31380453
http://dx.doi.org/10.22038/AOJNMB.2019.13348
_version_ 1783439432445067264
author Komek, Halil
Ansal Balci, Tansel
Can, Canan
author_facet Komek, Halil
Ansal Balci, Tansel
Can, Canan
author_sort Komek, Halil
collection PubMed
description OBJECTIVE(S): The aim of this study was to determine metastasis rate in patients with well-differentiated grade1 (G1) and grade 2 (G2) gastroenteropancreatic neuroendocrine tumors (GEP NETs) using the gallium-68 DOTATATE positron emission tomography/computed tomography ((68)Ga-DOTATATE PET/CT). This study was also targeted toward investigating the relationship of maximum standardized uptake value (SUV(max)) with mitotic count, histological grade, and Ki-67 index. METHODS: This retrospective study included 38 patients (i.e., 17 males and 21 females) with G1 or G2 GEP NETs who underwent (68)Ga-DOTATATE PET/CT in Diyarbakir Gazi Yasargil training and research hospital between November 2014 and March 2018. The patients had at least one positive lesion that was approved by two nuclear medicine specialists with a minimum of 10 years of experience. RESULTS: The median age of the patients was 50 years (age range: 27-80 years), and their mean age was 52±15 years. Out of 38 patients, 1 (2.6%), 2 (5.2%), 2 (5.2%), 3 (7.8%), 10 (28.5%), and 19 (50%) patients had primary hepatic, primary mesenteric, colon, duodenal, gastric, and pancreatic NETs, respectively. In addition, the liver metastasis, local lymph node invasions, distant lymph node metastasis, bone metastasis, peritoneal involvement, and lung metastasis were observed in 42%, 21%, 15.7%, 13%, 7.8%, and 5% of the cases, respectively. The SUV(max) median values of G1 and G2 tumors were 9.45 (range: 4.2-43.6) and 34.9 (range: 4.1-103), respectively (P=0.003). The Ki-67 index showed a negative correlation with the SUV(max) value of the liver metastases and the highest SUV(max) value (P=0.001 and P=0.002, respectively). There was also a negative correlation between mitosis count and the highest SUV(max) value (P=0.011). CONCLUSION: Based on the findings, although [(68)Ga]DOTATATE PET/CT is successfully used to diagnose primary GEP NETs and their metastases, the SUV(max) value obtained from DOTATATE PET/CT showed a negative correlation with Ki-67 and mitotic count.
format Online
Article
Text
id pubmed-6661313
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Mashhad University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-66613132019-08-02 Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Komek, Halil Ansal Balci, Tansel Can, Canan Asia Ocean J Nucl Med Biol Original Article OBJECTIVE(S): The aim of this study was to determine metastasis rate in patients with well-differentiated grade1 (G1) and grade 2 (G2) gastroenteropancreatic neuroendocrine tumors (GEP NETs) using the gallium-68 DOTATATE positron emission tomography/computed tomography ((68)Ga-DOTATATE PET/CT). This study was also targeted toward investigating the relationship of maximum standardized uptake value (SUV(max)) with mitotic count, histological grade, and Ki-67 index. METHODS: This retrospective study included 38 patients (i.e., 17 males and 21 females) with G1 or G2 GEP NETs who underwent (68)Ga-DOTATATE PET/CT in Diyarbakir Gazi Yasargil training and research hospital between November 2014 and March 2018. The patients had at least one positive lesion that was approved by two nuclear medicine specialists with a minimum of 10 years of experience. RESULTS: The median age of the patients was 50 years (age range: 27-80 years), and their mean age was 52±15 years. Out of 38 patients, 1 (2.6%), 2 (5.2%), 2 (5.2%), 3 (7.8%), 10 (28.5%), and 19 (50%) patients had primary hepatic, primary mesenteric, colon, duodenal, gastric, and pancreatic NETs, respectively. In addition, the liver metastasis, local lymph node invasions, distant lymph node metastasis, bone metastasis, peritoneal involvement, and lung metastasis were observed in 42%, 21%, 15.7%, 13%, 7.8%, and 5% of the cases, respectively. The SUV(max) median values of G1 and G2 tumors were 9.45 (range: 4.2-43.6) and 34.9 (range: 4.1-103), respectively (P=0.003). The Ki-67 index showed a negative correlation with the SUV(max) value of the liver metastases and the highest SUV(max) value (P=0.001 and P=0.002, respectively). There was also a negative correlation between mitosis count and the highest SUV(max) value (P=0.011). CONCLUSION: Based on the findings, although [(68)Ga]DOTATATE PET/CT is successfully used to diagnose primary GEP NETs and their metastases, the SUV(max) value obtained from DOTATATE PET/CT showed a negative correlation with Ki-67 and mitotic count. Mashhad University of Medical Sciences 2019 /pmc/articles/PMC6661313/ /pubmed/31380453 http://dx.doi.org/10.22038/AOJNMB.2019.13348 Text en © 2019 mums.ac.ir All rights reserved This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Komek, Halil
Ansal Balci, Tansel
Can, Canan
Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
title Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
title_full Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
title_fullStr Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
title_full_unstemmed Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
title_short Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
title_sort efficacy of galium-68 dotatate pet/ct in the detection of metastasis rate of well-differentiated gastroenteropancreatic neuroendocrine tumors
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661313/
https://www.ncbi.nlm.nih.gov/pubmed/31380453
http://dx.doi.org/10.22038/AOJNMB.2019.13348
work_keys_str_mv AT komekhalil efficacyofgalium68dotatatepetctinthedetectionofmetastasisrateofwelldifferentiatedgastroenteropancreaticneuroendocrinetumors
AT ansalbalcitansel efficacyofgalium68dotatatepetctinthedetectionofmetastasisrateofwelldifferentiatedgastroenteropancreaticneuroendocrinetumors
AT cancanan efficacyofgalium68dotatatepetctinthedetectionofmetastasisrateofwelldifferentiatedgastroenteropancreaticneuroendocrinetumors